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4-Hydroxyproline metabolism and 
glyoxylate production: A target 
for substrate depletion in primary 
hyperoxaluria?
MB Coulter-Mackie1,2
The primary hyperoxalurias are diseases of overproduction of oxalate. 
The immediate precursor of oxalate is glyoxylate. Metabolism of 
hydroxyproline, derived from collagen turnover or the diet, appears to 
be a major source of glyoxylate, and a potential target for a therapeutic 
strategy of substrate depletion.
Kidney International (2006) 70, 1891–1893. doi:10.1038/sj.ki.5001987
Th e paper by Knight et al.1 in this issue of 
Kidney International has added more sup-
port to the possibility that hydroxyproline 
and its metabolites in the mitochondria 
make a major contribution to the pro-
duction of glyoxylate. Glyoxylate is the 
immediate precursor of oxalate, a sim-
ple dicarboxylic acid that has no known 
functional role in animals and is toxic to 
most organisms. Animals cannot metabo-
lize oxalate and do not normally store it. 
Rather, oxalate is excreted in urine. Th e 
primary hyperoxalurias (PH1 and PH2) 
are rare genetic diseases wherein oxalate 
is generated in amounts exceeding the 
body’s ability to handle it, resulting in 
supersaturation in urine and crystalli-
zation forming calcium oxalate kidney 
stones.2 PH1 is caused by a defi ciency of 
alanine:glyoxylate aminotransferase-1 
(AGT1), and PH2 by a defi ciency of gly-
oxylate reductase (GR). Both PH1 and 
PH2 lead to excretion of abnormally high 
quantities of oxalate and development 
of calcium oxalate crystals and stones in 
the kidney. Th e primary site for oxalate 
production is the liver, although the toxic 
manifestations of oxalosis develop in the 
kidney and in other organs. PH1 eventu-
ally culminates in renal failure aft er sev-
eral years. PH2 has a less severe course.
AGT1 is expressed mainly in the liver. 
Its subcellular location is normally per-
oxisomal in humans and other primates, 
mitochondrial in dogs and cats, and both 
peroxisomal and mitochondrial in rats 
and mice. Its function is to convert gly-
oxylate to glycine (Figure 1). Expression 
of GR is highest in the liver, but it is also 
expressed in other tissues. GR is located 
in mitochondria and cytoplasm. Its func-
tion is to convert glyoxylate to glycolate. 
Both AGT1 and GR are main players in 
the removal of glyoxylate, preventing its 
conversion to oxalate.2,3
Treatment options for the hyperoxalu-
rias are limited. A recent review4 consid-
ers classic treatments as well as some new 
approaches. A subset of PH1 patients ben-
efi ts from pyridoxine supplementation. 
Liver transplantation is an eff ective treat-
ment, for PH1 especially, because the liver 
is the major site of expression of AGT1. It 
has not been used for PH2. Gene therapy 
approaches would require repopulation of 
the majority of hepatocytes, but this may 
not suffi  ce for PH2 because of the expres-
sion of GR in more diverse tissues. Th e use 
of chemical chaperones to stabilize pro-
teins with missense mutations, allowing 
them to evade intracellular quality control 
surveillance and achieve functional activ-
ity, is an area of interest in many human 
genetic diseases, including PH1. However, 
both PH1 and PH2 are genetically hetero-
geneous, and many mutations in both, 
especially PH2, are expected to yield no 
protein product. Th ere are also situations 
in which a protein product is produced 
but the mutation is manifested in ways 
other than loss of biological stability, such 
as a direct eff ect on catalysis. Substrate 
depletion is a therapeutic approach with 
general applicability independent of the 
specifi c genetic defect. Substrate depletion 
therapy has been investigated in conjunc-
tion with lysosomal storage disorders, but 
the concept applies here as well. Th e sub-
strate in this case is glyoxylate, the imme-
diate precursor of oxalate. Is it possible to 
control the production of glyoxylate when 
its normal clearance is blocked?
By necessity, in order to manipulate a 
metabolic pathway, one has to understand 
the regulation, interaction, and subcellu-
lar distribution of the reactions, be aware 
of alternate or secondary catalytic activi-
ties and side reactions, and recognize 
the sources of metabolites that feed the 
pathway. Th e focus falls mainly on gly-
colate oxidase (GO), GR, and AGT1 as 
the enzymes at the end of the pathway to 
oxalate and on glyoxylate as the precur-
sor. Such studies have been complicated 
by diffi  culties in measuring low levels of 
metabolites in cells, and lack of suitable 
cellular or animal models.2,5,6 Th is has 
been further complicated by the diff er-
ent compartmentalization of the com-
ponents of the pathway in humans as 
compared with the animals that would 
normally be used as research models.2 
Human hepatoma cells (HepG2) have 
been used in several studies,5,7 as have 
rat hepatocytes. Although HepG2 cells 
provide a good model for some aspects 
of the pathway, there are diff erences in 
the peroxisomal membrane permeability 
compared with that of liver hepatocytes. 
Isolated mitochondria have been used to 
investigate the mitochondrial components 
of the pathway.8
A promising model system developed 
by Benham et al.6 uses Chinese hamster 
ovary cells stably transfected with all 
combinations of human GO, GR, and 
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AGT1 genes. Chinese hamster ovary 
cells do not endogenously produce these 
enzymes. This system can be used to 
investigate the interaction of the enzyme 
reactions in a pathway where all three 
enzymes are functioning or where one 
(for example, AGT1 or GR) is defi cient. 
Subcellular localization of enzymes is 
appropriate. Th is system also provides a 
model where potential pharmacological 
agents can be tested.
Using data from these and other stud-
ies, the pathways to glyoxylate and oxalate 
can be outlined (Figure 1). Th e major sites 
of production of endogenous glyoxylate 
are the peroxisomes and the mitochon-
dria. Glycolate is the major precursor of 
glyoxylate. In the peroxisome, glyoxylate 
can be derived from glycine through the 
reaction of d-amino acid oxidase or, more 
signifi cantly, from imported glycolate by 
reaction with GO. Glyoxylate can also be 
imported into peroxisomes from the cyto-
plasm. Glyoxylate is normally removed by 
transamination with alanine and AGT1, 
producing pyruvate and glycine. Excess 
glyoxylate in peroxisomes is converted 
to oxalate by GO or is transported out 
to the cytoplasm, where it is converted 
to oxalate by lactate dehydrogenase. Th e 
former reaction is normally a minor role 
for GO5 but may become signifi cant if 
AGT1 is defi cient.
Glyoxylate is also produced in mito-
chondria through metabolism of 4-
hydroxyproline (Hyp). Mitochondrial 
glyoxylate is converted to glycolate 
through the action of GR or to glycine by 
AGT2 (Figure 1). AGT2 is distinct from 
AGT1, and its location in human mito-
chondria has been recently confi rmed.5 
AGT1 is not normally found in mitochon-
dria in humans. In the absence of GR, 
glyoxylate will be converted to oxalate.
Interest has developed recently in the 
possible role of Hyp as a signifi cant source 
of glyoxylate. Hyp is derived from meat 
and gelatin in the diet and from normal 
turnover of collagen. In a study of rats, 
Takayama et al.9 demonstrated increased 
excretion of oxalate and glycolate in ani-
mals given Hyp. A prior injection with 
glucagon, demonstrated to induce mito-
chondrial AGT1, reduced the response to 
Hyp. Th e amount of Hyp given is admit-
tedly severalfold higher than normal 
dietary levels, but the experiment indi-
cated that oxalate can be formed in vivo 
from Hyp by metabolism to glyoxylate.
Studies with isolated mouse liver mito-
chondria8 demonstrated that incubation 
with Hyp substantially increased glyoxy-
late production. Moreover, Khan et al.10 
described the use of Hyp to induce hyper-
oxaluria and nephrolithiasis in rats.
Knight et al.1 present the most recent 
investigations into the role of metabolism 
of Hyp in glyoxylate and oxalate produc-
tion in humans. Th e authors examined the 
eff ect of dietary Hyp from gelatin on nor-
mal human volunteers. Th ey showed that 
urinary oxalate and glycolate increased 
significantly after ingestion of large 
amounts of Hyp. Th ere was a proportional 
relationship between the amount of gela-
tin consumed and the urinary oxalate and 
glycolate produced. In addition, the results 
suggested that the kidney reabsorbs signi-
fi cant quantities of Hyp and may contri-
bute to the conversion of Hyp to glyoxylate 
through mitochondrial metabolism.
How important is the contribution of 
Hyp to glyoxylate? It was estimated that 
the normal breakdown of collagen con-
tributes 20%–50% of excreted glycolate 
and up to 20% of urinary oxalate pro-
duced endogenously.1,8 In PH1, where 
AGT1 is absent, combined excretion of 
glycolate and oxalate may be in the range 
of 200–500 mg per day.1,8 Th e amount 
of Hyp degraded per day is 300–400 mg. 
Th is suggests that Hyp metabolism may 
be a major contributor to the glycolate→
glyoxylate→oxalate pathway. In PH2, 
excretion of oxalate and glycolate is lower, 
consistent with a functional AGT1 remov-
ing a portion of the glyoxylate.1,8
It seems reasonable to consider the path 
of degradation of Hyp as a suitable target 
for a substrate depletion strategy aimed at 
decreasing the generation of glyoxylate. It 
has been proposed8 that Hyp analogues 
might be eff ective in blocking transport 
of Hyp into cells or mitochondria, or 
inhibiting normal metabolism of Hyp in 
mitochondria (Figure 1).
With the experimental model systems 
now available and enticing data such as 
those from Knight and colleagues,1,8 
this will be a promising new direc-
tion for development of therapies for 
hyperoxaluria.
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Figure 1 | Simplifi ed metabolic pathways leading to glyoxylate and oxalate. This fi gure outlines 
the major reactions under discussion, their subcellular locations, and potential sites for intervention 
to achieve substrate (glyoxylate) depletion. AGT, alanine:glyoxylate aminotransferase; DAO, D-amino 
acid oxidase; GO, glycolate oxidase; GR, glyoxylate reductase; LDH, lactate dehydrogenase; HKGA, 
4-hydroxy-2-ketoglutarate lyase. Solid arrows: enzymatic reactions; broken arrows: transport: proposed 
sites for intervention.
Kidney International (2006) 70       1893
commentar y
ACKNOWLEDGMENTS
Research in my laboratory is supported by a 
grant from the Canadian Institutes of Health 
Research.
REFERENCES
1. Knight J, Jiang J, Assimos DG, Holmes RP. 
Hydroxyproline ingestion and urinary oxalate 
and glycolate excretion. Kidney Int 2006; 70: 
1929–1934. 
2. Danpure CJ. Primary hyperoxaluria. In: Scriver CR, 
Beaudet AL, Sly WS, Valle D (eds). The Metabolic 
and Molecular Bases of Inherited Disease, 8th edn. 
McGraw-Hill: New York, 2001, pp 3323–3367.
3. Holmes RP, Assimos DG. Glyoxylate synthesis 
and its modulation and influence on oxalate 
synthesis. J Urol 1998; 160: 1617–1624.
4. Danpure C. Molecular etiology of primary 
hyperoxaluria type 1: new directions for 
treatment. Am J Nephrol 2005; 25: 303–310.
5. Baker PRS, Cramer SD, Kennedy M et al. Glycolate 
and glyoxylate metabolism in HepG2 cells. 
Am J Cell Physiol 2004; 287: C1359–C1365.
6. Behnam JT, Williams EL, Brink S et al. 
Reconstruction of human hepatocyte glyoxylate 
metabolic pathways in stably transformed 
Chinese hamster ovary cells. Biochem J 2006; 394: 
409–416.
7. Holmes RP, Sexton WJ, Applewhite JC et al. 
Glycolate metabolism by HepG2 cells. J Am Soc 
Nephrol 1999; 10: S345–S347.
8. Knight J, Holmes R. Mitochondrial 
hydroxyproline metabolism: implications for 
primary hyperoxaluria. Am J Nephrol 2005; 
25: 171–175.
9. Takayama T, Fujita K, Suzuki M et al. Control of 
oxalate formation from L-hydroxyproline in liver 
mitochondria. J Am Soc Nephrol 2003; 
14: 939–946.
10. Khan SR, Glenton PA, Byer KJ. Modeling of 
hyperoxaluric calcium oxalate nephrolithiasis: 
experimental induction of hyperoxaluria by 
hydroxy-L-proline. Kidney Int 2006; 70: 914–923.
see original article on page 1983
The broader burden of end-stage 
renal disease on children and their 
families
AL Friedman1–3
When a child has end-stage renal disease and requires dialysis, a 
heavy personal and financial toll can be extracted from the caregivers 
and the family. Tsai et al. have demonstrated an adverse effect on the 
psychosocial and socioeconomic well-being of caregivers of children 
on chronic peritoneal dialysis. These findings raise other questions and 
force us to think about support for the caregiver as well as the patient.
Kidney International (2006) 70, 1893–1894. doi:10.1038/sj.ki.5001964
Th at end-stage renal disease (ESRD) is 
medically difficult for patients is well 
known to patients and their caregivers. 
Th e documented myriad of changes as a 
result of poor renal function and dialytic 
support involves essentially all organ sys-
tems from cardiovascular eff ects to central 
nervous system changes.1 Superimposed 
on all the physical and cognitive changes 
experienced by patients is the impact of 
ESRD on the aff ective mental health of 
patients and on the health and economic 
well-being of patients’ families. Th is latter 
issue — the physical, mental, and fi nan-
cial health of families — is an area of more 
recent study.2,3
Objective measures of mental health 
and socioeconomic well-being are more 
widely used. Th e techniques for studying 
the mental health and social integration 
of children have taken longer to develop, 
and therefore studies looking at the impact 
of chronic disease on the children and 
their families are now, with increasing 
frequency, entering the literature.3 Th e 
publication by Tsai et al.4 (this issue) points 
to basic issues surrounding the care of chil-
dren with chronic renal diseases. Invari-
ably children with chronic disease require 
the help of parents, guardians, or others 
in order to survive. Children, including 
adolescents, cannot and should not be 
expected to manage their disease with-
out the help of competent adults. Adults 
oft en need support. Children need direct 
involvement and supervision. Th erefore, 
the physical, mental, and economic health 
of caregivers will profoundly infl uence the 
outcome for children. Th e observation by 
Tsai et al.4 that probable depression was 
three times more likely to be found in car-
egivers of children on peritoneal dialysis 
than in caregivers of normal children, and 
that caregivers of children on peritoneal 
dialysis were less likely to hold a full-time 
job and, on average, earned less than care-
givers of normal children, is very impor-
tant to understanding the overall impact 
of this form of chronic disease on children 
and families.
These observations raise questions and 
concerns.
The association of socioeconomic 
status with medical outcome is well 
documented.5 Th e association of socio-
economic status and chronic illness with 
family functionality is also documented.6 
Chronic disease in a child, especially 
a condition that entails loss of control, 
has a negative impact on families, mak-
ing them more dysfunctional. But some 
questions have not yet been answered 
clearly by Tsai et al.4 and others: Do fami-
lies become more dysfunctional as a result 
of the chronic illness? Does this increas-
ing dysfunctionality lead to a lowering of 
socioeconomic status and a worsening 
of medical outcomes? Is there a cycle in 
which dysfunctionality and lower socio-
economic status positively feed back on 
each other (Figure 1)?
Children with chronic diseases increase 
the stress on families by adding the 
responsibility of caring for the ill and 
the fear of more serious illness or death.7 
Th ese families have a poor sense of coher-
ence and reduced functionality.8 Tsai et 
al.4 and others9 have found that psychiat-
ric symptoms in the caregivers of chroni-
cally ill children are more common and 
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